PTPN1 and obesity due to melanocortin 4 receptor deficiency: It is reported that AMF could inhibit protein tyrosine phosphatase 1B (PTP1B) activity, therefore AMF has been proposed as a strategy for the treatment of T2D and obesity (Na et al., 2007).